About Daan Biotherapeutics
Daan Biotherapeutics is a Healthcare company based in Seoul (South Korea) founded in 2020 by J Y Han. Therapeutics for cancer treatment are developed using immune-based cell therapies. Daan Biotherapeutics has raised $17.21 million across 1 funding round from investors including Shinhan Financial Group, Atinum Investment and KB Investment. Its chief executive, as recorded, is Byoung Chul Cho. Its focus areas include Life Sciences, Oncology, Drugs and Lung Cancer. Its competitors include Bridge Biotherapeutics and GeneCraft; 2 of its 2 listed competitors have raised funding.
Company details
Daan Biotherapeutics was founded in 2020 in Seoul, South Korea. Operations are centered in the biotechnology sector, where therapeutics for cancer treatment are developed. Immune-based cell therapies are focused on lung cancer, with T Cell Receptors (TCR) derived from natural killer cells used to target EGFR mutations. The company is led by founder J Y Han and CEO Byoung Chul Cho.
- Headquarters Seoul, South Korea
- Founders J Y Han
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website daanbiotpx.com
- Total Equity Funding$17.21M (USD)
in 1 rounds
- Latest Funding Round$17.21M (USD), Series A
Jan 2024
- InvestorsShinhan Financial Group
& 10 more
Funding Insights of Daan Biotherapeutics
Daan Biotherapeutics has successfully raised a total of $17.21M through 1 strategic funding round. The most recent funding activity was a Series A round of $17.21 million completed in January 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $17.21M
- Total Rounds 1
- Last Round Series A — $17.21M
- First Round $17.21M
(Jan 2024)
- Investors Count 11
All 1 funding rounds of Daan Biotherapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2024 | $17.21M | Series A | – | Solasta Ventures, Company K Partners | – |
11 investors in total: 11 institutional.
Investors in Daan Biotherapeutics
Daan Biotherapeutics has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Shinhan Financial Group, Atinum Investment and KB Investment.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on healthcare startups | solasta-ventures.com | Boston, United States | ||
Venture capital firm investing in tech startups | 2006 | kpartners.co.kr | Seoul, South Korea | |
Strategic investments are made in high-growth companies by Paratus Investment. | paratusinvestment.com | Seoul, South Korea | ||
VC firm investing in geographies such as South Korea | 1988 | atinuminvest.co.kr | Seoul, South Korea | |
Early-stage tech and life sciences focused VC & PE firm | stonebridge.co.kr | Seoul, South Korea | ||
Dayli Partners is focused on bio-healthcare and fintech investments. | dayli.partners | Seoul, South Korea | ||
Venture capital fund investing in early-stage tech startups | 1990 | kbic.co.kr | Seoul, South Korea | |
| solidusvc.com | ||||
Financial group | 1982 | shinhangroup.com | Seoul, South Korea | |
FuturePlay is engaged in startup investment and acceleration. | futureplay.co | Seoul, South Korea |
Investor details for Daan Biotherapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Daan Biotherapeutics
2 people are tracked at Daan Biotherapeutics (2 in leadership).
| Name | Role | Group |
|---|---|---|
J Y Han | Founder | Leadership |
Byoung Chul Cho | CEO | Leadership |
Complete people profiles for Daan Biotherapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Daan Biotherapeutics
2 dated milestones of Daan Biotherapeutics across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Daan Biotherapeutics is founded.
- Funding First funding round of $17.2M.
Competitors of Daan Biotherapeutics
Daan Biotherapeutics has 2 listed competitors in our database, 2 of them funded. They include Bridge Biotherapeutics and GeneCraft.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebiorx.com | 2015 | Seongnam-si, South Korea | $10M | 6 | Small molecule therapeutics are developed for treating various diseases. | |
| genecraft.co.kr | 2020 | Cheongju-si, South Korea | $7.61M | Gene therapies for cancer treatment are developed using AAV vectors. |
Detailed competitors of Daan Biotherapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Daan Biotherapeutics
The website of Daan Biotherapeutics (daanbiotpx.com) receives about 3.9K visits a month.
- Monthly visits3.9K
▲ 12.6% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Daan Biotherapeutics
Complete news archive for Daan Biotherapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Daan Biotherapeutics
Daan Biotherapeutics was founded in 2020 and raised its 1st funding round 4 years after it was founded.
Daan Biotherapeutics is headquartered in Seoul, South Korea.
Byoung Chul Cho is the CEO of Daan Biotherapeutics, as recorded in our data.
Daan Biotherapeutics is a funded company, having raised a total of $17.21M across 1 funding round to date. The company's 1st funding round was a Series A of $17.21M, raised on Jan 2024.
Daan Biotherapeutics was founded in 2020 in Seoul, South Korea. Operations are centered in the biotechnology sector, where therapeutics for cancer treatment are developed. Immune-based cell therapies are focused on lung cancer, with T Cell Receptors (TCR) derived from natural killer cells used to target EGFR mutations. The company is led by founder J Y Han and CEO Byoung Chul Cho.
Daan Biotherapeutics's top competitors include Bridge Biotherapeutics and GeneCraft.
Daan Biotherapeutics has 11 investors. Key investors include Shinhan Financial Group, Atinum Investment, KB Investment, Company K Partners, and Solasta Ventures.